Skip to content Skip to navigation

Ablynx

Ablynx

Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. The unique structure and stability of Nanobodies® has allowed Ablynx, and its partners, to pursue targets that are typically difficult to reach with conventional antibodies.

Ablynx
Ablynx nv
Technologiepark 4
Ghent/Zwijnaarde, 9052
Belgium
view on map

http://www.Ablynx.com
info@ablynx.com
+32 (0)9 262 00 00

Type: 
Industry

InterNano Taxonomy: